The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 526-533

  Tang, Dabei ^a   Xu, Shanqi ^a   Zhang, Qingyuan ^a,b   Zhao, Wenhui ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Oncobiology Key Lab of Heilongjiang Common Institution of Higher Learning   (China)

Author keywords

Androgen receptor; E cadherin; Metastasis; Prognosis; Recurrence; Triplenegative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; UVOMORULIN; AR PROTEIN, HUMAN; CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BREAST TUMOR; CANCER INVASION; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG CARCINOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864472736     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9948-2     Document Type: Article

References (32)

1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
2. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.
3. Rakha EA, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42:3149-56.
4. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer Registry. Cancer. 2007;109:1721-8.
5. Rakha EA, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
6. Koo JS, Jung W, Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer. Jpn J Clin Oncol. 2009;39:560-8.
7. Kashiwagi S, et al. Significance of E-cadherin expression in triple- negative breast cancer. Br J Cancer. 2010;103:249-55.
8. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res. 2009;11:212.
9. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010;16:62-5.
10. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol. 2008;61:615-20.
11. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-54.
12. Alizadeh AA, Ross DT, Perou CM, Ven de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2010;195:41-52.
13. Kashiwagi S, et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103:249-55.
14. Riva C, et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch. 2005;447:695-700.
15. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725-31.
16. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18:112-8.
17. Rakha EA, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
18. Dogu GG, et al. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol. 2010;27:34-9.
19. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585-90.
20. Narita D, Raica M, Suciu C, Cimpean A, Anghel A. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer. Folia Histochem Cytobiol. 2006;44:165-72.
21. Bryan RM, et al. Androgen receptors in breast cancer. Cancer. 1984;54:2436-40.
22. Kuenen-Boumeester V, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996;32A:1560-5.
23. Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.
24. Gould RBE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat. 2006;100:139-48.
25. Rakha EA, Abd ERD, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46:685-93.
26. Graff JR, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195-9.
27. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48:365-75.
28. Perez-Moreno MA, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem. 2001;276:27424-31.
29. Makdissi FB, et al. Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas. Braz J Med Biol Res. 2009;42:1128-37.
30. Montserrat N, et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort. Hum Pathol. 2011;42:103-10.
31. Vesuna F, van DP, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235-41.
32. Liu YN, Liu Y, Lee HJ, Hsu YH, Chen JH. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol. 2008;28:7096-108.